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A B S T R A C T
Background: The prevalence of antidepressant prescribing in children and adolescents increased steadily in the
United States and parts of Europe between 2005 and 2012 despite regulatory safety warnings. Little is known
about the characteristics of those being prescribed antidepressants for the ﬁrst time.
Methods: A longitudinal study of antidepressant prescribing in 3–17 year olds was carried out using data from
the UK Clinical Practice Research Datalink (CPRD) between 2000 and 2015. Changes in the incidence of ﬁrst
ever antidepressant prescriptions and the characteristics of those being prescribed them was examined.
Results: Incidence of ﬁrst ever prescriptions nearly doubled between 2006 and 2015 rising from 1.60 (95%CI:
1.51, 1.69) to 3.12 (3.00, 3.25) per 1000 person years. Only 21% of the 1721 patients with incident
prescriptions in 2015 could be linked to a depression diagnosis, with an additional 22% of prescriptions linked
to alternative indications. The incidence of prescriptions linked to a depression diagnosis increased between
2012 and 2015, with an adjusted incidence rate ratio of 1.46 (1.26, 1.70). Antidepressant prescribing for
depression and other indications has been increasing most rapidly in 15 to 17 year old females.
Limitations: Diagnoses are not directly linked to prescriptions in CPRD, so linkage must be inferred by
temporal proximity.
Conclusions: Antidepressant prescribing in children increased between 2006 and 2015. This is, at least in part,
due to a rise in alternative uses of antidepressants, including the treatment of anxiety, chronic pain and
migraines.
1. Introduction
Antidepressant prescribing rates in children and adolescents in-
creased throughout the 1990s in the United States (US) (Chen and Toh,
2011; Skaer et al., 2009) and other parts of the Western world (Hall
et al., 2003; Murray et al., 2004; Shatin and Drinkard, 2002), only to go
into sharp decline between 2002 and 2006 (Chen and Toh, 2011;
O'Sullivan et al., 2015; Wijlaars et al., 2012).
In 2004 the US Food and Drug Administration (FDA) directed
pharmaceutical companies to add warnings about an increased risk of
suicidal thoughts and behaviours associated with antidepressant use in
under 18 year olds treated for depression and other psychiatric
disorders to their product information (FDA, 2004), with similar
warnings being issued across Europe (EMA, 2005; Weller et al., 2004).
This action was taken in response to reports by the FDA (FDA,
2004), the Medicines and Healthcare Products Regulatory Agency
(MHRA) in the UK (Weller et al., 2004) and the European Medicines
Agency (EMA, 2005), which extended warnings of a small increase in
the risk of suicidal thoughts and behaviours in children and adoles-
cents, initially reported for the selective serotonin reuptake inhibitor
(SSRI) paroxetine in 2003 (Hammad, 2004; Le Noury et al., 2015), to
other antidepressants. They also stated that only the SSRI ﬂuoxetine
had been consistently shown to be eﬀective in the treatment of
depression in under 18 year olds (FDA, 2004; EMA, 2005; Weller
et al., 2004). These conclusions were primarily based on an examina-
tion of data from the limited number of short-term placebo-controlled
trials of antidepressant in children and adolescent with depression and
other psychiatric disorders available at the time, for the FDA report this
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was 24 trials of 9 antidepressants (FDA, 2004).
These reports built on existing concerns about the use of tricyclic
antidepressants (TCAs) to treat depression in this age group due to the
risk of seizure and cardiovascular side-eﬀects associated with TCA
overdose and previous reports of lack of eﬃcacy (Geller et al., 1999;
Hazell and Mirzaie, 2013). In 2005, the UK National Institute for
Health and Care Excellence (NICE) issued guidelines for the treatment
of depression in 5 to 17 year olds that clearly stated that TCA's should
not be used in this age group. They also recommend that antidepres-
sants should only be used with caution and in conjunction with
continued psychological therapy if the patient was unresponsive to
psychological therapy alone (NICE, 2005a, 2005b).
However, despite these widely publicised warnings and the intro-
duction of new guidelines, antidepressant prescribing in under 19's
increased between 2005 and 2012 in the US, UK and other European
countries (Bachmann et al., 2016). Additionally TCAs still accounted
for approximately 20% of all antidepressants prescribed to under 19
year olds in the UK and Germany in 2012. This was nearly twice that
reported for the US, but in contrast to Germany and the UK, where the
use of TCAs in children appears to be decreasing the US, Denmark and
the Netherlands all showed a slight increase in TCA prescribing
between 2005 and 2012 (Bachmann et al., 2016).
The reasons behind this increase in antidepressant prescribing in
children and adolescents are still unclear, as are the reasons for the
continued high level of TCA prescribing in this age group. However the
increasing number of alternative uses for antidepressants is likely to be
a contributing factor (Chouinard, 2006; Stone et al., 2003). This
includes licensed and well accepted uses that are part of age-appro-
priate treatment guidelines, such as the treatment of obsessive-
compulsive disorder (OCD) (Chouinard, 2006; NICE, 2005c), anxiety
(cBNF, 2015a) and neuropathic pain (cBNF, 2015b), and uses that are
either not yet well supported or in some cases potentially inappropri-
ate. Attitudes towards the use of antidepressants in children and young
people with mental health conditions has also undergone changes as
recent research, mainly focused on ﬂuoxetine, suggests that the safety
and eﬃcacy of antidepressant treatment in this age group is higher
than previously thought (Cox et al., 2014; Gibbons et al., 2012).
Information gained from monitoring changes in patterns of anti-
depressant prescribing, and the characteristics of those being pre-
scribed them, can be used to evaluate the eﬀectiveness of current
guidelines in limiting antidepressants prescribing in speciﬁc groups
(Hetrick et al., 2012). Additionally early identiﬁcation of new trends in
alternative uses for antidepressants can prompt the timely develop-
ment of appropriate guidance and allow any gaps in the evidence base
supporting current prescribing decisions to be addressed.
Approximately 98% of the UK population is registered with a general
practice (HSCIC, 2015). This makes longitudinal anonymised UK
primary care data a powerful tool for identifying new trends in
antidepressant prescribing. This study takes advantage of this to
examine whether or not current trends in UK primary care antide-
pressant prescribing in children have continued in recent years and
what proportion of this can be linked to depression diagnoses. It also
examines changes in the characteristics of 3–17 year olds prescribed
their ﬁrst antidepressant between 2000 and 2015. The indications for
which these prescriptions were issued in 2015 were examined, as was
the use of TCAs in depression and for other indications.
2. Methods
2.1. Data source
The Clinical Practice Research Datalink (CPRD; www.cprd.com)
records anonymised routinely collected data from general practices
across the UK. Clinical events (diagnoses and symptoms), therapies
(prescriptions), referrals and tests are identiﬁed using codes.
Approximately 6.9% of the UK population belong to practices
participating in the CPRD, which provides a cohort of patients that
are broadly representative of the UK general population in terms of
age, sex and ethnicity (Herrett et al., 2015).
2.2. Study population
This consisted of all children and adolescents aged 3–17 years
registered with a general practice contributing to the CPRD between
the 1st of January and 31st of December who met the following
inclusion criteria annually between 2000 and 2015: (i) Patients entered
the cohort either at the beginning of the study window, on the 1st of
January the year they turned age 3, when they had been registered at
the practice for 6 months, or when the data returned by the practice
was oﬃcially deemed by CPRD to be up to standard for conducting
academic research. (ii) Patients remained in the cohort until the end of
the study's observation period, or until they transferred out of their
registered practice, reached age 18, died, or the date of the last data
collection for their registered practice was reached.
2.3. Antidepressant prescribing trends, 2000−2015
The annual prevalence of 3–17 year olds prescribed one or more
antidepressant and the annual incidence of ﬁrst ever antidepressant
prescriptions were determined for each calendar year between 2000
and 2015. A ﬁrst ever antidepressant prescription was deﬁned as the
ﬁrst ever recording of an antidepressant prescription in the CPRD.
Prevalence and incidence by age, gender and antidepressant class
(selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepres-
sant (TCA), other antidepressant) were explored. Age was measured on
the 1st of January. Age bands were set at 3–5 years, 6–11 years, 12–14
years and 15–17 years old. This is in line with the child development
stages set down by the Centers for Disease Control and Prevention
(CDC, 2015) and the UK's educational national curriculum ‘key stage’
blocks (Gov.uk, 2015).
Comparisons in incidence and prevalence between speciﬁc years
were made using rate ratios derived from a two-level Poisson regres-
sion model. The two-level structure allowed for practices entering and
leaving the CPRD by including random eﬀects at the practice level. Age,
gender and the practice level index of multiple deprivation (IMD) 2010
quintile were included as categorical covariates. The IMD covers seven
aspects of deprivation, including health deprivation and disability,
education and employment (CLG, 2011). All analyses were undertaken
using Stata, version 13 (Stata Corp, College Station, Texas).
2.4. Depression code lists
Codes for depression diagnoses were identiﬁed by comparing 6
publicly available code lists (Doran et al., 2011; Kendrick et al., 2015;
Martinez et al., 2005; Moran et al., 2015; Rait et al., 2009; Wijlaars
et al., 2012). Search terms identiﬁed during this comparison were used
to identify any additional codes following a previously described
protocol (Dave and Petersen, 2009). Depression codes mapping to
International Statistical Classiﬁcation of Diseases and Related Health
Problems version 10 (ICD-10) or a similar clearly deﬁned depression
diagnoses were included. Codes for depression presenting comorbidly
with another psychiatric condition, for example ‘[X]Mixed anxiety and
depressive disorder’, or where depressive symptoms are a signiﬁcant
part of a disorder, for example ‘Schizoaﬀective disorder, depressive
type’ where also included. All code lists are available via clinicalcode-
s.org (Springate et al., 2014). All code lists were reviewed by the study
team, which included a general practitioner, a consultant in child and
adolescent psychiatry, a pharmacist and epidemiologists with experi-
ence in mental health research.
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2.5. Alternative uses for antidepressants
Alternative uses for antidepressants in children and adolescents
were assigned to one of two levels. Level 1 groups consisted of clinical
codes for a condition or group of related conditions where the uses of
an antidepressant was included as a treatment option in either NICE
guidelines that covered at least part of the age range under study, or the
children's edition of the British national formulary (cBNF) as of
December 2015. Level 2 groups consisted of i) clinical code groupings
identiﬁed during this study as part of a survey of clinical codes recorded
on the same day as a ﬁrst ever antidepressant prescription in 2015 with
a frequency of over 1%. ii) Symptom code groups; deﬁned as codes not
meeting the criteria for a depression or anxiety diagnosis. For example
‘Depressed mood’, ‘Suspected depression’, ‘Low mood’ and ‘Anxious’.
As some of the relevant clinical codes refer to linked groups of
disorders rather than a speciﬁc condition some level 1 groups were
broadened or merged. For example NICE guidelines diﬀer in their
recommendations towards antidepressant use in the eating disorders
between anorexia nervosa and bulima nervosa in the absence of
comorbid depression but the clinical code “[X]Eating disorders” can
be used for both so in this study the disorders are grouped together
(NICE, 2004).
Level 1 conditions/condition groups are: 1) obsessive-compulsive
disorder (OCD) (Chouinard, 2006; NICE, 2005c), 2) headache dis-
orders (expanded from migraine) (NICE, 2012), 3) neuropathic and
chronic pain (cBNF, 2015b), 4) bedwetting (NICE, 2010); 5) attention
deﬁcit hyperactivity disorder (ADHD) (NICE, 2008b); 6) eating dis-
orders (NICE, 2004) and 7) anxiety (cBNF, 2015a) (Fig. 1). Code lists
for these conditions were created using the same method as the
depression code list (Dave and Petersen, 2009).
2.6. Diagnoses linked to ﬁrst ever antidepressant prescriptions in
2015
The clinical codes used in CPRD are not directly linked to a speciﬁc
prescription, so the association can only be made by temporal
proximity. To allow for gaps between diagnosis and the start of
antidepressant treatment or delays in recording diagnoses from non-
primary care settings a diagnosis was considered to be contemporary if
it occurred between 12 weeks prior and 4 weeks after the recording of a
ﬁrst ever antidepressant prescription. Two sensitivity analyses were
carried out to assess the eﬀect of changing the size of this assessment
window: First, a restricted analysis using only clinical codes recorded
on the same day as the ﬁrst ever antidepressant prescription and
second an expanded analysis covering one year prior to the ﬁrst ever
prescription to 4 weeks after it.
Some patients could have contemporary recording of clinical codes
for multiple relevant conditions. For example, it is common for
children and adolescents diagnosed with depression to also have
another mental health disorder, including OCD and anxiety, or a
physical condition including pain and headaches (Emslie and Mayes,
2001). To account for multiple conditions, patients were assigned to a
clinical code group using the following hierarchy of rules (Fig. 1):
1) A contemporary diagnosis of depression was always considered to
be the primary reason for a ﬁrst ever antidepressant prescription.
2) A code from a level 1 group outranked a code from a level 2 group.
3) A code recorded on the day of the ﬁrst ever antidepressant
prescription outrank a contemporary code.
Diﬀerences between clinical code groups in terms of gender,
antidepressant class prescribed and age at time of ﬁrst ever prescrip-
tion were examined. Children aged 3–5 years were excluded from this
analysis due to the negligible number of ﬁrst ever prescriptions
recorded in this age band.
2.7. Changes in depression diagnosis and symptom codes linked to
incident antidepressant prescribing, 2000−2015
Changes in the incidence of 6–17 year olds receiving an antide-
pressant prescription with a contemporary depression diagnosis code
versus those with a recording of a depression symptom code in the
absence of an alternative indication between 2000 and 2015 were
investigated. An alternative indication was taken to be a contemporary
recording of a code from a level 1 or 2 clinical code group, excluding
anxiety symptoms (Fig. 1). The impact of changes in the demographics
of the study population and the eﬀect of altering the time window used
to assign patients to code groups was investigated using the same
protocol described for the primary incidence and prevalence analyses.
The study protocol was approved by the Independent Scientiﬁc
Advisory Committee of the MHRA (protocol number 16–071).
3. Results
3.1. Antidepressant prescribing trends
Distinct changes in the direction of prescribing frequency for both
the incidence and prevalence of 3–17 year olds prescribed antidepres-
sant were observed in 2002 and 2006. Incidence dropped from 3.16
(95% CI: 3.03, 3.30) to 1.61 (1.51, 1.69) for ﬁrst ever prescriptions per
1000 person years (Fig. 2) and percent prevalence from 0.47 (0.45,
0.49) to 0.24 (0.23, 0.25) (Supplemental Figure 1). After adjusting for
changes in population demographics and taking clustering within
practice into account this equated to a halving of both incidence and
prevalence with an incidence rate ratio of 0.48 (0.45, 0.52) and a
prevalence rate ratio of 0.48 (0.46, 0.51). This reversed the increase in
antidepressant prescribing in this age group seen between 2000 and
2002. However, this decreased frequency of prescribing did not persist
with the observed prevalence of antidepressant prescribing in children
surpassing the previous 2002 high in 2014, with a percentage
prevalence of 0.49 (0.47, 0.50) in 2015. Incidence increased to 3.07
(3.93, 3.22) per 1000 person years in 2015. Adjusted rate ratios for
2015 relative to 2006 were 1.95 (1.80, 2.10) for incidence and 2.20
Fig. 1. Flow chart for assignment of 6–17 year olds with a ﬁrst ever antidepressant
prescription in 2015 by prescribing indication. A code recorded 12 week before to 4
weeks after the ﬁrst ever prescription was considered to be contemporary. A con-
temporary recording of a depression diagnosis code was considered to be the primary
reason for the antidepressant prescription followed by level 1, then level 2 diagnostic
code groupings. Level 1 diagnostic code groups are for conditions that have antidepres-
sant use included in age appropriated NICE guidelines or the BNF for children. Levels 2
were either identiﬁed in a survey of codes recorded on the day of the ﬁrst ever
prescription in 2015 or consist of symptom codes. *Less than 5 events recorded.
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(2.07, 2.35) for prevalence.
Young people aged 15–17 showed the greatest increase in the
incidence of ﬁrst ever prescriptions between 2006 and 2015 (Fig. 2),
with an adjusted incidence rate ratio of 2.13 (1.96, 2.32). This age
group accounted for 75% of 3–17 year olds prescribed an antidepres-
sant for the ﬁrst time in 2006 and 82% in 2015. In contrast the number
of 6–11 year olds prescribed an antidepressant decreased during this
time period with an adjusted incidence rate ratio of 0.70 (0.52, 0.95).
The number of 3–5 year olds receiving a ﬁrst ever prescription was
negligible at all time points, so this age group was not included in
further analysis. Females were more than twice as likely as males to
receive a ﬁrst ever antidepressant prescription between 2006 and 2015
with an adjusted rate ratio of 2.49 (2.41, 2.57) and showed the greatest
increase over time with an adjusted incidence rate ratio for 2015
compared to 2006 of 2.15 (1.97, 2.36) with males showing a smaller
increase at 1.59 (1.39, 1.81).
The quantity and type of prescriptions issued also changed between
2006 and 2015, with the number of antidepressant prescriptions issued
per 1000 person years rising from 9.2 (8.97, 9.39) to 24.3 (23.9, 24.71)
and the proportion of prescriptions issued for non-SSRI dropping from
33–16%. The proportion of non-SSRIs prescriptions issued to those
receiving their ﬁrst ever antidepressant prescription dropped from 38–
22%.
3.2. Diagnoses codes linked to a ﬁrst ever antidepressant prescription
in 2015
A total of 62.8% of recipients of a ﬁrst ever antidepressant aged 6–
17 were not assigned to either the depression diagnosis group or a level
1 group in 2015 (Table 1). Depression (21.4%) followed by anxiety
(6.0%) were the most common assignments. The characteristics of
those within each diagnostic group also diﬀered, with those issued a
ﬁrst ever antidepressant prescription for enuresis being more likely to
be male and aged 5–14 than members of any other demographic
subgroup. In keeping with the children's version of the British national
formulary (cBNF) and NICE guidelines non-SSRIs were mostly pre-
scribed to those with enuresis (NICE, 2010), pain (cBNF, 2015b), and
headache disorders (NICE, 2012). The most commonly prescribed non-
SSRI was amitriptyline which accounted for 86% of all non-SSRI ﬁrst
ever antidepressant prescriptions in 2015.
Of the diagnostic code groups identiﬁed in the survey of codes
recorded on the same day as the incident prescription only the ‘irritable
bowel syndrome and abdominal pain’ code group could be linked to
over 1% of patients. Another category of codes identiﬁed in this survey
were those indicating interaction with a mental health service, includ-
ing codes indicating they had been referred to/seen by a mental health
service provider or were being treated/monitored for a mental health
condition. The largest level 2 code group was depression symptoms at
13.3% (Fig. 1/Table 1). A total of 43.6% of patients were not assigned
to a diagnostic code group of which 28.2% (12.1% of the total) had a
contemporary recording of a code indicating interaction with a mental
health service (Fig. 3).
Expanding the time window within which relevant diagnostic codes
were considered to be linked to the ﬁrst ever antidepressant prescrip-
tion to a year prior before the prescription and 4 weeks after resulted in
only an additional 14% of patients being assigned to a group. This
reduced the un-assigned group from 44–30%, while restricting the
window to codes recorded on the same day as the prescription left 62%
un-assigned (Supplemental Table 1). Additionally even using the
expanded time window 34% (10.1% of the total) of un-assigned
patients had a recording of a code indicating interaction with a mental
health service within the expanded time window.
3.3. Changes in ﬁrst ever prescriptions linked to depression diagnosis
and symptom codes, 2000 – 2015
The incidence of patients assigned to both the depression diagnosis
and depression symptom code groups showed an increase between
2006 and 2015. The observed incidence of ﬁrst ever antidepressant
prescriptions with a contemporary recording of a depression diagnosis
code increased from 0.51 (0.45, 0.56) per 1000 person years in 2006 to
0.81 (0.73, 0.90) in 2015 (Fig. 4), with an adjusted incident rate ratio of
1.60 (1.37, 1.87). The majority of this increase occurred between 2012
and 2015 with an adjusted incidence rate ratio of 1.46 (1.26, 1.70).
Depression symptom codes linked to a ﬁrst ever prescription started to
increase from 2006 rising from 0.19 (0.15, 0.22) per 1000 person years
to 0.50 (0.44, 0.57) in 2015, with an adjusted incidence rate ratio of
2.75 (2.19, 3.46).
4. Discussion
4.1. Summary of the study's ﬁndings
In 2014 the prevalence of children prescribed antidepressants in
the UK surpassed the level seen prior to the introduction of govern-
mental guidelines and product warnings aimed at limiting the use of
antidepressants in the treatment of depression in children and
adolescents during the early 2000's (FDA, 2004; EMA, 2005; NICE,
2005b; Weller et al., 2004) (Supplemental Figure 1). Young women
aged 15–17 accounted for most of this rise, accounting for 61% of all
ﬁrst ever prescriptions in 2015, with females in general being more
than twice as likely as males to be prescribed a ﬁrst ever antidepressant
at all time points (Fig. 2). The proportion of ﬁrst ever prescriptions that
could be linked to a contemporary depression diagnosis increased
sharply after 2012 (Fig. 4) but still only accounted for 21% of
prescriptions in 2015, with a further 13% linked to depression
symptom codes. An additional 22% were linked to other clinical code
groups with 44% remaining un-assigned (Table 1), 28% of which had a
contemporary recording of a code indicating interaction with a mental
health service.
The majority of TCA's were prescribed to those in the pain,
headache disorders or enuresis code groups in line with the appropriate
NICE guidelines (cBNF, 2015b; NICE, 2012, 2010), or were un-
assigned. A total of 90% of TCA prescriptions were for amitriptyline.
Only 1% of those with a contemporary depression diagnosis received a
non-SSRI prescription, which is in keeping with NICE guidelines which
state that ‘Tricyclic antidepressants should not be used for the
treatment of depression in children and young people’ (NICE,
2005b). A total of 43% of depression linked prescription were for
Fig. 2. Changes in rates of 3–17 year olds starting antidepressant treatment for the ﬁrst
time, Key: (1) The investigative program Panorama raises concerns about the use of the
SSRI paroxetine in children. (2) The FDA request that GlaxoSmithKline provide clinical
trial data of paroxetine in children revealing an increased risk of suicidal behaviour. (3)
The FDA and MHRA complete investigations into antidepressant safety and eﬃcacy in
children. (4) The FDA requires that safety warnings be added to antidepressants. (5)
NICE introduces guidelines for the treatment of depression in children which recom-
mends limitations on antidepressant use.
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ﬂuoxetine, the NICE recommended ﬁrst line antidepressant treatment,
and 35% for sertraline and citalopram, which are suggested as
alternatives antidepressants if treatment with ﬂuoxetine is ineﬀective
(NICE, 2005b).
4.2. Comparison with other studies
Bachmann et al. (2016) reported that the prevalence of under 19
year olds prescribed antidepressants increased in the US and four
European countries (UK, Germany, Denmark and the Netherlands)
between 2006 and 2012. This study supports the Bachmann et al.
(2016) UK ﬁndings using a second anonymised primary care data set,
including those for TCA prescribing levels. Additionally it shows that
the prevalence of 3–17 year olds prescribed antidepressants continued
to increase between 2012 and 2015 (Supplemental Figure 1). The
Bachmann et al. (2016) study also reported that Germany and the UK
prescribe similar levels of TCAs vs SSRIs.
The pattern of alternative uses of antidepressants for this study
appears to be similar to those reported in a German study, including
only 22% of children treated with antidepressant having a depression
diagnosis between 2004 and 2006 (Dorks et al., 2013). Similarly a 2012
US study reported that only 28% of all subjects had a diagnosis
consistent with an FDA-approved indication within 30 days pre-index
and post-index antidepressant (Czaja and Valuck, 2012). In this study
an increase in prescriptions linked to depression diagnoses was noted
after 2012, this increase was most marked in 15–17 year old females. A
recent survey of English 14 year olds reported that the mental
wellbeing of teenage girls has worsened since 2005 with 37% reporting
symptoms of psychological distress, over twice that reported by their
male counterparts (Lessof et al., 2016), which may help to explain this
gender speciﬁc rise. However, attitudes towards the use of antidepres-
sants in children and adolescents are also shifting. The latest revision of
NICE guidelines on the treatment of depression in children issued in
2015 supports the use of antidepressants as part of the initial treatment
for 12–18 year olds with moderate to severe depression, whereas in the
past the recommendation has been that antidepressants only be used in
a child or young person who is unresponsive to an initial psychological
intervention (NICE, 2005b). This change in guidance was based on a
review of recent ﬁndings (NICE, 2015), including those from the
treatment of adolescents with depression study which reported the
highest rate of treatment response for combined ﬂuoxetine and
cognitive behavioural therapy (71%), followed by ﬂuoxetine alone
(61%). Those in the cognitive behavioural therapy alone arm of the
study only achieved a response rate of 43% (March et al., 2004). This
may indicate that at least part of this increase is due to an increased
willingness to prescribe antidepressants to children with depression.
4.3. Strengths and Limitations
The CPRD is one of the largest longitudinal primary healthcare data
set in the world. It is broadly representative of the UK population and
contains a record of all prescriptions issued by participating GPs
(Herrett et al., 2015) making it a powerful tool for epidemiological
studies. It does however have some limitations. Population demo-
graphics may change over time as practices enter and leave the CPRD.
Table 1
Characteristics of patients prescribed a first ever antidepressant in 2015 by clinical code group. Groups are assigned on the basis of codes recorded contemporarily (−12weeks to
+4weeks) to the first ever recorded antidepressant prescription. *Data for groups consisting of less than 5 patients is not shown. # Summary statistics for patients not assigned to
depression diagnosis group or a level 1 diagnostic group.
Percent Total Incidence per 1000 PYs (95% Conﬁdence
Intervals)
Percent Female Percent aged 15–17 Percent prescribed SSRI
Depression diagnosis 21.4% 0.81 (0.73, 0.90) 75% 91% 99%
Level 1 diagnostic groups
Anxiety 6.0% 0.23 (0.19, 0.28) 67% 89% 93%
Pain (chronic, neuralgia) 4.3% 0.16 (0.13, 0.20) 84% 86% 5%
Headache disorder 2.3% 0.09 (0.06, 0.12) 77% 69% 18%
OCD 1.4% 0.05 (0.03, 0.08) 54% 50% 100%
Enuresis 0.9% 0.04 (0.02, 0.06) 44% 0% 0%
Eating disorder 0.8% 0.03 (0.02, 0.05) 86% 86% 100%
ADHD* – – – – –
Other# 62.8% 2.38 (2.24, 2.53) 70% 81% 77%
Level 2 diagnostic groups
Abdominal pain or IBS 2.3% 0.09 (0.06, 0.12) 72% 72% 46%
Depression symptoms 13.3% 0.50 (0.44, 0.57) 78% 93% 98%
Anxiety Symptoms 3.7% 0.14 (0.11, 0.18) 68% 89% 92%
Un-assigned 43.6% 1.65 (1.54, 1.78) 68% 77% 71%
Fig. 3. Changes in incidence of ﬁrst ever antidepressant prescriptions by age band and
gender.
Fig. 4. Changes over time in the incidence of ﬁrst ever antidepressant prescriptions
assigned to depression diagnosis vs depression symptom code groups.
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Prescriptions are not directly linked to a diagnosis, so temporal
proximity must be used to infer that link. Additionally diagnosis codes
may be missing, ambiguous or inaccurate, potentially leading to
misclassiﬁcation. NICE recommends that depression in children is
diagnosed and treated by a multidisciplinary team (NICE, 2005b,
2015) so the ﬁrst antidepressant prescription recorded in CPRD may
not be the ﬁrst ever prescription issued to the patient. This may explain
why 35% of the ﬁrst ever prescriptions recorded in CPRD for patients
with a contemporary depression diagnosis were for sertraline or
citalopram, which are recommended in NICE guidelines for use in
patients who have not responded to treatment with ﬂuoxetine (NICE,
2005b).
To account for changes in population demographics over time
adjusted rate ratios were calculated using a Poisson model. A con-
servative approach to the inclusion of potentially ambiguous codes was
used to improve the accuracy of diagnostic code group assignment,
although this may in turn lead to group sizes being underestimated. For
example, 28% of those not assigned to a diagnostic code group had a
contemporary recording of a code indicating that they were interacting
with a mental health service, including evidence of depression mon-
itoring. This, along with the relatively frequent use of depression
symptom codes, may also reﬂect clinician's unwillingness to ‘label’ a
child with a probably transitory depressive condition as having a
serious mental health disorder (Dowrick et al., 2009; Joling et al.,
2011; Mitchell et al., 2011). Two additional time windows in which
clinical codes were considered to be linked to the ﬁrst ever antide-
pressant prescription were also assessed, one restricted and the other
expanded from that used in the study (Supplemental Figure 1)
conﬁrming that the time window used is reasonable for capturing
relevant codes recorded by GPs.
4.4. Implications for clinicians and policymakers
There are an increasing number of alternative uses for antidepres-
sants and up to date age appropriate evidence based guidelines are not
always available. In this study irritable bowel syndrome (IBS) and
abdominal pain were linked to a ﬁrst ever prescription in 2% of case.
The use of antidepressants in the treatment of IBS is supported in
adults (NICE, 2008a) but no guidelines are available for children.
Humans can react diﬀerently to speciﬁc drugs at diﬀerent develop-
mental stages (de Wildt, 2011; Pichini et al., 2009), so it may not
always be appropriate to extrapolate ﬁnding in adult populations to
children and adolescents. Part of the reason for this lack of appropriate
guidance may be the limited number of studies looking at antidepres-
sant use in children and adolescents. Randomised controlled trials
(RCT), which provide some of the best evidence on the eﬃcacy and
safety of speciﬁc drug, are also often short term. In 2011 the FDA
issued a warning regarding a potential elevated risk of abnormal heart
rhythms with high doses of citalopram, which account for 17% of the
2015 prescriptions in this study. The only age-speciﬁc guidance given
in this warning was for adults aged over 60 (FDA, 2011). At the time
only 2 randomised clinical trials of citalopram had been carried out in
children (Carandang et al., 2011). More research is needed into the
long-term safety and clinical eﬀectiveness of antidepressant use in
children, including the use of large scale pharmacoepidemiological
studies to monitor trends in antidepressant prescribing.
The incidence of ﬁrst ever antidepressant prescriptions linked to
depression or a depression symptom code is increasing (Fig. 4). In part
this is likely to be a response to changing guidance on the treatment of
children with depression (Cox et al., 2014; NICE, 2015; Gibbons et al.,
2012) but also occurs at a time when child and adolescent mental
health services, which account for only 0.7% of the National health
service budget, are under increasing pressure in terms of budget cuts
and increased referrals (Barr et al., 2015; Frith, 2016).
Antidepressants, like ﬂuoxetine, are relatively inexpensive (BNF,
2016) particularly in comparison to psychological therapies, with
medication accounting of only 1% of spending on depression in the
UK (McCrone et al., 2008). Additionally the majority of ﬁrst ever
mental health related antidepressants were prescribed to 15–17 year
olds in this study. The transition between children and adolescent
mental health services and adult services most often occurs between 16
and 18 (NICE, 2016), presenting issues in gaining access to mental
health services for these young people. It is also an age range that is
important for academic and social development. In a recent UK study a
total of 24% of students aged 18–24 surveyed reported a mental health
problem, most commonly depression or anxiety, with nearly half
indicating that their mental health condition interfered with their
ability to complete daily task (YouGov.uk, 2016). This would seem to
suggest that additional resources should be targeted at this age group.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at doi:10.1016/j.jad.2016.12.047.
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